GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Beneish M-Score

Vivos Therapeutics (Vivos Therapeutics) Beneish M-Score : -3.66 (As of Jun. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.66 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vivos Therapeutics's Beneish M-Score or its related term are showing as below:

VVOS' s Beneish M-Score Range Over the Past 10 Years
Min: -6.25   Med: -4.32   Max: 0.5
Current: -3.66

During the past 6 years, the highest Beneish M-Score of Vivos Therapeutics was 0.50. The lowest was -6.25. And the median was -4.32.


Vivos Therapeutics Beneish M-Score Historical Data

The historical data trend for Vivos Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Beneish M-Score Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -2.78 -4.90 -5.30

Vivos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.90 -4.92 -6.25 -5.30 -3.66

Competitive Comparison of Vivos Therapeutics's Beneish M-Score

For the Medical Devices subindustry, Vivos Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Therapeutics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's Beneish M-Score falls into.



Vivos Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vivos Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.9873+0.528 * 1.0252+0.404 * 1.4286+0.892 * 0.823+0.115 * 1.2701
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8714+4.679 * -0.436462-0.327 * 1.3916
=-3.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.53 Mil.
Revenue was 3.419 + 3.248 + 3.301 + 3.395 = $13.36 Mil.
Gross Profit was 1.937 + 1.938 + 1.898 + 2.098 = $7.87 Mil.
Total Current Assets was $3.61 Mil.
Total Assets was $11.80 Mil.
Property, Plant and Equipment(Net PPE) was $4.63 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.59 Mil.
Selling, General, & Admin. Expense(SGA) was $23.35 Mil.
Total Current Liabilities was $8.07 Mil.
Long-Term Debt & Capital Lease Obligation was $1.40 Mil.
Net Income was -3.763 + -4.259 + -2.093 + -5.528 = $-15.64 Mil.
Non Operating Income was 0.022 + 0.025 + 1.396 + -1.011 = $0.43 Mil.
Cash Flow from Operations was -2.516 + -2.748 + -2.8 + -2.859 = $-10.92 Mil.
Total Receivables was $0.32 Mil.
Revenue was 3.857 + 3.95 + 4.246 + 4.184 = $16.24 Mil.
Gross Profit was 2.337 + 2.384 + 2.496 + 2.588 = $9.81 Mil.
Total Current Assets was $8.71 Mil.
Total Assets was $17.10 Mil.
Property, Plant and Equipment(Net PPE) was $4.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.80 Mil.
Selling, General, & Admin. Expense(SGA) was $32.56 Mil.
Total Current Liabilities was $7.98 Mil.
Long-Term Debt & Capital Lease Obligation was $1.88 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.525 / 13.363) / (0.321 / 16.237)
=0.039288 / 0.01977
=1.9873

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9.805 / 16.237) / (7.871 / 13.363)
=0.603868 / 0.589014
=1.0252

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.611 + 4.634) / 11.804) / (1 - (8.713 + 4.778) / 17.1)
=0.301508 / 0.211053
=1.4286

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=13.363 / 16.237
=0.823

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.803 / (0.803 + 4.778)) / (0.592 / (0.592 + 4.634))
=0.143881 / 0.11328
=1.2701

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(23.353 / 13.363) / (32.563 / 16.237)
=1.747587 / 2.005481
=0.8714

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.399 + 8.07) / 11.804) / ((1.882 + 7.975) / 17.1)
=0.802186 / 0.576433
=1.3916

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.643 - 0.432 - -10.923) / 11.804
=-0.436462

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vivos Therapeutics has a M-score of -3.66 suggests that the company is unlikely to be a manipulator.


Vivos Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129